CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 223 enrolled
Drug / intervention
Xermelodrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03223428
NCT03223428N/ACompleted
CompareCT.gov

An Observational Study to Evaluate the Real-world Experience of Patients Who Are Initiating Treatment With Telotristat Ethyl (XERMELO™)

TerSera Therapeutics LLC·observational·Posted Jul 21, 2017·Updated Jul 24, 2024

In Brief

An observational study evaluating Xermelo for Carcinoid Syndrome. Completed, enrolled 223 participants across 1 site.

Detailed Summary

The primary objective of the study is to estimate the proportion of carcinoid syndrome (CS) patients who are satisfied with their overall symptom control, 6 months after initiating treatment with telotristat ethyl (XERMELO).

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoid Syndrome
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedJul 21, 2017
Enrollment StartJun 22, 2017
Primary CompletionJan 14, 2022
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 8.9 years ago

Interventions

Xermelodrug

This study will include patients with carcinoid syndrome who are initiating treatment with XERMELO.